DK1835922T3 - Kombinationsbehandling mod multipel sklerose - Google Patents

Kombinationsbehandling mod multipel sklerose

Info

Publication number
DK1835922T3
DK1835922T3 DK05823965T DK05823965T DK1835922T3 DK 1835922 T3 DK1835922 T3 DK 1835922T3 DK 05823965 T DK05823965 T DK 05823965T DK 05823965 T DK05823965 T DK 05823965T DK 1835922 T3 DK1835922 T3 DK 1835922T3
Authority
DK
Denmark
Prior art keywords
multiple sclerosis
cda
alpha
agent
combination therapy
Prior art date
Application number
DK05823965T
Other languages
Danish (da)
English (en)
Inventor
Luca Giampiero De
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Application granted granted Critical
Publication of DK1835922T3 publication Critical patent/DK1835922T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Transplanting Machines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05823965T 2004-12-22 2005-12-20 Kombinationsbehandling mod multipel sklerose DK1835922T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63867404P 2004-12-22 2004-12-22
EP04106910 2004-12-22
PCT/EP2005/056943 WO2006067134A1 (en) 2004-12-22 2005-12-20 Combination treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
DK1835922T3 true DK1835922T3 (da) 2009-08-03

Family

ID=35789196

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05823965T DK1835922T3 (da) 2004-12-22 2005-12-20 Kombinationsbehandling mod multipel sklerose

Country Status (17)

Country Link
US (1) US20100129353A1 (sl)
EP (1) EP1835922B1 (sl)
JP (1) JP2008524310A (sl)
AT (1) ATE431740T1 (sl)
AU (1) AU2005318183B2 (sl)
CA (1) CA2590471A1 (sl)
CY (1) CY1109316T1 (sl)
DE (1) DE602005014570D1 (sl)
DK (1) DK1835922T3 (sl)
ES (1) ES2325552T3 (sl)
HR (1) HRP20090417T1 (sl)
IL (1) IL183924A (sl)
NO (1) NO20073635L (sl)
PL (1) PL1835922T3 (sl)
PT (1) PT1835922E (sl)
SI (1) SI1835922T1 (sl)
WO (1) WO2006067134A1 (sl)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) * 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) * 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5077211A (en) * 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
GB9206318D0 (en) * 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6225447B1 (en) * 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5565332A (en) * 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ES2341666T3 (es) * 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5208327A (en) * 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ATE199392T1 (de) * 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
GB9712818D0 (en) * 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
SI2336184T1 (sl) * 2002-02-25 2015-04-30 Biogen Idec Ma Inc. Dajanje sredstev za zdravljenje vnetij
MEP34508A (en) * 2003-03-28 2011-02-10 Ares Trading Sa Cladribine formulations for improved oral and transmucosal delivery

Also Published As

Publication number Publication date
EP1835922A1 (en) 2007-09-26
AU2005318183A1 (en) 2006-06-29
US20100129353A1 (en) 2010-05-27
EP1835922B1 (en) 2009-05-20
ES2325552T3 (es) 2009-09-08
IL183924A0 (en) 2007-10-31
SI1835922T1 (sl) 2009-10-31
DE602005014570D1 (sl) 2009-07-02
CY1109316T1 (el) 2014-07-02
PL1835922T3 (pl) 2009-10-30
WO2006067134A1 (en) 2006-06-29
IL183924A (en) 2010-11-30
HRP20090417T1 (en) 2009-09-30
ATE431740T1 (de) 2009-06-15
AU2005318183B2 (en) 2011-03-31
CA2590471A1 (en) 2006-06-29
PT1835922E (pt) 2009-07-08
NO20073635L (no) 2007-09-24
JP2008524310A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
GB2506085A (en) Combination treatment (eg with ABT-072 or ABT-333) of DAAS for use in treating HCV
CY1116463T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
NO332893B1 (no) Anvendelse av antistoff for fremstilling av medikament til anvendelse ved CVP-kjemoterapi
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
NO20064287L (no) Dalbavancin-materialer for behandling av bakterielle infeksjoner
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
DE60114406D1 (de) Wirkstoffabgabesysteme zur behandlung von gefässerkrankungen
WO2003049694A3 (en) Methods of therapy for non-hodgkin's lymphoma
SG160323A1 (en) Methods for controlling angiogenesis and cell proliferation
MXPA05005338A (es) Metodos para administrar dalbavancin para el tratamiento de infecciones bacterianas.
DK1140198T3 (da) Anvendelse af hyaluronan til fremstilling af et lægemiddel til forögelse af cytotoksiske lægemidlers virkningsgrad
CY1113488T1 (el) Ενα φαρμακο για την δυο βαθμιδων περιεγχειρητικη θεραπεια συμπαγων ογκων δια ραδιοανοσοθεραπειας
BR0310061A (pt) Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições
ATE413187T1 (de) Pharmazeutische zusammensetzungen mit interferon- tau
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
BR0317539A (pt) Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais
JP2003528919A5 (sl)
DK1835922T3 (da) Kombinationsbehandling mod multipel sklerose
HK1045456A1 (en) Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection
TW200628162A (en) Combination treatment for multiple sclerosis
EA200801670A1 (ru) Комбинированная противораковая терапия с перфузией изолированного органа
RU2008137226A (ru) Способ и композиция для защиты от радиации
TH100271B (th) การบำบัดแบบมีการรวมสำหรับโรคปลอกประสาทเสื่อมแข็ง